Cyrus Biotechnology, Inc. announced that it has received $18.352692 million in funding from a group of investors

On December 2, 2021, Cyrus Biotechnology, Inc. closed the transaction. The company amended the terms of the transaction. The company received $2,410,524 in third tranche brining total gross proceeds raised to $18,352,692.

The transaction included participation from The Yard Ventures, iSelect Fund Management, LLC, Trinity Ventures Ltd., Washington Research Foundation, Selecta Biosciences, Inc., new investor Agent Capital, LLC, returning investors The W Fund, a fund managed by University of Washington, Endowment Arm, OrbiMed Advisors LLC and other 26 investors including family offices, and individual investors. The company expects to receive $19,352,692 in the transaction.